Disclosed is a method for prophylaxis or treatment of infection of a virus, or for modulating innate immunity, in a subject comprising administering to the subject a therapeutically effective amount of a PUM1 inhibitor. A pharmaceutical composition comprising the PUM1 inhibitor is also disclosed.

A method of preparing a ddx27-deletion zebrafish mutant, including: determining a target of ddx27 knockout on a sixth exon of the ddx27 in a zebrafish and designing a gRNA sequence; using primers T7-ddx27-sfd and tracr rev for PCR amplification with a pUC19-gRNA scaffold plasmid as a template; purifying and transcribing the PCR product obtained in vitro to produce gRNA; introducing the gRNA and a Cas9 protein into the zebrafish; and culturing the zebrafish to obtain a zebrafish ddx27 mutant of stable inheritance. In addition, the application also discloses a phenotype of the ddx27-deletion zebrafish mutant, which plays an important role in investigating the biological function.

This disclosure provides, among other things, amplifiable nucleic acid constructs for expressing a gene of interest in a cell, e.g., an erythroid cell. The amplifiable nucleic acid construct may contain the gene of interest and an RNA-dependent RNA polymerase (RdRP)-responsive 5 UTR, and may optionally further contain an RdRP-responsive 3 UTR. RdRP may also be provided, e.g., on the same construct or a different construct.

The present invention relates to a pharmaceutical combination comprising a recombinant Gram-negative bacterial strain and an immune checkpoint modulator (ICM) and their use in a method for the prevention, delay of progression or treatment of cancer in a subject.

Embodiments of the disclosure include chemical, genetic, and/or computational systems, methods, and compositions for characterizing RNA helicases for targeting for inhibition, and methods of screening for inhibitors. In specific embodiments, inhibitors of RNA helicases, including RNA helicases for splicing, are identified that have selective targeting of one or more desired RNA helicases but that are also counter-selected such that the inhibitor does not target one or more RNA helicases that would result in toxicity.

Immunogenic compositions and methods of their use in eliciting immune responses to coronaviruses, such as SARS-CoV-2 are provided.

A nucleic acid molecule encoding a fusion protein composed of a plant cryptochrome at the amino terminus, and a GTPase-Activating Protein SH3 Domain-Binding Protein (G3BP) is provided for light-dependent, G3BP-mediated stress granule formation.

Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.

The invention relates to a method for preventing, ameliorating or treating disease caused by dengue virus in a subject in need thereof comprising administering to the subject a dengue vaccine formulation in combination with a NS3 helicase polypeptide and/or fragment(s) thereof, wherein said method comprises stimulating humoral as well as cell-mediated immunity to the dengue virus in the subject.

The invention relates to a method for preventing, ameliorating or treating disease caused by dengue virus in a subject in need thereof comprising administering to the subject a dengue vaccine formulation in combination with a NS3 helicase polypeptide and/or fragment(s) thereof, wherein said method comprises stimulating humoral as well as cell-mediated immunity to the dengue virus in the subject.